Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility

• This tablet press will provide the facility's Formulation Development Team with an important tool for developing fixed dose combinations and modified release drug delivery.
• Piramal Pharma Solutions has implemented robust training protocols to ensure safe operation and high-quality output from the XM-12.

MUMBAI, India, Sept. 16, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is excited to announce its recent acquisition of a state-of-the-art Korsch XM-12 bilayer tablet press at its drug product facility in Morpeth, UK. The Morpeth facility plays a vital role in the company's integrated offering, providing specialized services for the development and manufacturing of oral solids and hormonal products.